Pure Global AI
NCT05834751Not yet recruiting

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Clinical Study on the Effectiveness and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor Injection and PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma.
Ou Bai, MD/PHDClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
PEG-rhG-CSF
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ou Bai, MD/PHD
Funder
The First Hospital of Jilin University
Location
Changchun, China
Timeline & enrollment
Phase
N/A
Start date
May 01, 2023
End date
Jul 01, 2025
Enrollment
144 participants
Primary outcome

Mobilization success rate

Summary

A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and
 safety of pegylated recombinant human granulocyte stimulating factor injection in the
 mobilization of autologous hematopoietic stem cells in lymphoma.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05834751
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05834751 through Pure Global AI's free database. This phase not specified trial is sponsored by Ou Bai, MD/PHD and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 144 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.